Published in Oncogene on September 01, 1991
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol (2001) 2.69
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer (1991) 2.52
p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol (2010) 2.34
Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res (1992) 2.07
Role of cysteine residues in regulation of p53 function. Mol Cell Biol (1995) 1.91
Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol (1996) 1.65
Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet (1999) 1.57
Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol (1992) 1.56
Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation. Mol Cell Biol (1998) 1.52
In situ characterization of inflammatory responses in the rectal mucosae of patients with shigellosis. Infect Immun (1997) 1.36
p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol (1995) 1.32
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica (2009) 1.31
Apoptosis and its relationship with cell proliferation, p53, Waf1p21, bcl-2 and c-myc in esophageal carcinogenesis studied with a high-risk population in northern China. World J Gastroenterol (1998) 1.30
Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J (2000) 1.26
Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol (1993) 1.25
Ras activation of genes: Mob-1 as a model. Proc Natl Acad Sci U S A (1994) 1.25
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest (2011) 1.21
Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer (1994) 1.21
Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci U S A (1996) 1.21
p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer (1992) 1.19
Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity. J Virol (1992) 1.18
Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer (1993) 1.16
p53 mutations in cervical carcinogenesis--low frequency and lack of correlation with human papillomavirus status. Br J Cancer (1994) 1.11
Chaperone-mediated autophagy degrades mutant p53. Genes Dev (2013) 1.11
Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS One (2012) 1.11
Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer (1994) 1.08
p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer (1994) 1.07
Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer (1995) 1.07
Radiation-induced intercellular signaling mediated by cytochrome-c via a p53-dependent pathway in hepatoma cells. Oncogene (2010) 1.04
The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer (1994) 1.04
Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. Am J Pathol (1994) 1.00
TP53: an oncogene in disguise. Cell Death Differ (2015) 1.00
Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol (1993) 0.99
Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol (1993) 0.99
Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci U S A (2000) 0.99
Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol (1993) 0.98
Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer (1994) 0.98
p53 protein expression in central nervous system neoplasms. J Clin Pathol (1992) 0.97
Immunohistochemical analysis of p53 expression in anal squamous neoplasia. J Clin Pathol (1993) 0.96
Genetically engineered mouse models for skin research: taking the next step. J Dermatol Sci (2008) 0.94
Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol (1993) 0.91
MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J Biol Chem (2010) 0.90
p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer (1996) 0.88
Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol (2003) 0.87
Overexpression of p53 protein in human tumors. Med Mol Morphol (2012) 0.87
Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. BMC Cancer (2006) 0.87
p53 expression in carcinoma of the cervix. J Clin Pathol (1996) 0.87
Targeting tumor suppressor networks for cancer therapeutics. Curr Drug Targets (2014) 0.87
p53 protein accumulation in oesophageal squamous cell carcinomas and precancerous lesions. J Clin Pathol (1995) 0.86
Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer. J Clin Pathol (2006) 0.86
Expression of mutant p53 protein in hepatocellular carcinoma. Gut (1994) 0.86
p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med (2013) 0.85
Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases. Virchows Arch (2004) 0.85
Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature. Protein Sci (2006) 0.85
Differences in p53 and Bcl-2 expression in relation to cell proliferation during the development of human embryos. Mol Pathol (1998) 0.81
High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br J Cancer (1997) 0.81
Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination. Mol Cancer Res (2016) 0.81
Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. J Cancer Res Clin Oncol (1997) 0.80
Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease. Proc Natl Acad Sci U S A (1993) 0.80
p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event. Clin Mol Pathol (1995) 0.80
Converting cancer genes into killer genes. Proc Natl Acad Sci U S A (1996) 0.80
p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer (1993) 0.79
Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage. Oncotarget (2015) 0.79
The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. J R Soc Med (1995) 0.78
Expression of the p53 protein in malignant melanomas as a prognostic indicator. Arch Dermatol Res (1995) 0.78
p53 protein is absent from the serum of patients with lung cancer. Br J Cancer (1996) 0.77
p53 increase mitochondrial copy number via up-regulation of mitochondrial transcription factor A in colorectal cancer. Oncotarget (2016) 0.76
p53 gene alterations and protein accumulation in colorectal cancer. Clin Mol Pathol (1996) 0.75
Significance of Wet Autoclave Pretreatment in Immunohistochemistry. Pathol Oncol Res (1996) 0.75
Localization and Molecular Characterization of human Breast Cancer Initiating Cells from heterogeneous population of Breast Cancer Mesenchymal Stem cells by Immunofluorescence Microscopy. J Stem Cells Regen Med (2012) 0.75
Immunohistochemistry of whole-organ sections of advanced human laryngeal cancer. Eur Arch Otorhinolaryngol (2006) 0.75
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
Cancer. p53, guardian of the genome. Nature (1992) 16.36
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J (1990) 6.34
Regulation of the specific DNA binding function of p53. Cell (1992) 6.16
Negative regulation of viral enhancers in undifferentiated embryonic stem cells. Cell (1985) 5.88
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
An immunoaffinity purification procedure for SV40 large T antigen. Virology (1985) 4.81
Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell (1993) 4.62
SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene (1990) 3.89
Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol (1986) 3.72
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 3.49
SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature (1980) 3.44
Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci (1990) 3.35
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res (1994) 3.28
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods (1992) 3.23
Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci (1992) 3.18
High levels of p53 protein in UV-irradiated normal human skin. Oncogene (1993) 3.15
Using the polymerase chain reaction to modify expression plasmids for epitope mapping. Nucleic Acids Res (1989) 3.15
Two pathways for base excision repair in mammalian cells. J Biol Chem (1996) 3.01
Small peptides activate the latent sequence-specific DNA binding function of p53. Cell (1995) 2.96
Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A (1997) 2.90
Requirement for the replication protein SSB in human DNA excision repair. Nature (1991) 2.80
Nuclear protein with sequence homology to translation initiation factor eIF-4A. Nature (1988) 2.77
Use of monoclonal antibodies as probes of simian virus 40 T antigen ATPase activity. J Biol Chem (1981) 2.77
Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature (1991) 2.75
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol (1991) 2.71
A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol (1995) 2.57
An immunochemical investigation of SV40 T antigens. 1. Production properties and specificity of rabbit antibody to purified simian virus 40 large-T antigen. Virology (1978) 2.49
p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol (1994) 2.41
Structure and function of SV40 large-T antigen. Philos Trans R Soc Lond B Biol Sci (1987) 2.37
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology (1991) 2.32
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A (1998) 2.28
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep (2001) 2.27
Allosteric activation of latent p53 tetramers. Curr Biol (1994) 2.25
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol (1997) 2.25
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene (2001) 2.14
DbpA: a DEAD box protein specifically activated by 23s rRNA. EMBO J (1993) 2.04
Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature (1991) 1.99
Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene (1999) 1.98
Nuclear protein p68 is an RNA-dependent ATPase. EMBO J (1989) 1.98
p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet (1991) 1.95
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94
Autoradiographic study of mannan incorporation into the growing cell walls of Saccharomyces cerevisiae. J Bacteriol (1974) 1.94
A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair. Nucleic Acids Res (1992) 1.91
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology (1983) 1.78
Origins of the prestalk-prespore pattern in Dictyostelium development. Cell (1989) 1.78
Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays (1995) 1.75
Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol (1995) 1.75
An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res (1999) 1.74
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res (2001) 1.73
Cancer. A death in the life of p53. Nature (1993) 1.70
The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays (1993) 1.70
p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts. Mol Cell Biol (1991) 1.69
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer (1990) 1.69
Isolation and analysis of the fission yeast gene encoding polymerase delta accessory protein PCNA. EMBO J (1992) 1.68
Molecular characterization of the hdm2-p53 interaction. J Mol Biol (1997) 1.64
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol (1992) 1.62
Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci (1995) 1.57
Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet (1992) 1.53
Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci U S A (2000) 1.52
Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene (1995) 1.51
Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res (1993) 1.49
Ku selectively transfers between DNA molecules with homologous ends. J Biol Chem (1997) 1.46
Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol (1991) 1.46
The p53 response to ionising radiation in adult and developing murine tissues. Oncogene (1996) 1.46
APC expression in normal human tissues. J Pathol (1997) 1.44
The complex between simian virus 40 T antigen and a specific host protein. Proc R Soc Lond B Biol Sci (1980) 1.41
Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene (1991) 1.40
Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell (1992) 1.39
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
Identification of novel mdm2 binding peptides by phage display. Oncogene (1996) 1.37
Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer (1994) 1.37
Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene (2008) 1.37
The p53 tumour suppressor gene. Br J Surg (1998) 1.37
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ (2010) 1.36
Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer (1993) 1.36
Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene (1991) 1.36
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ (2010) 1.35